These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 29679556)
1. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Pan W; Luo Q; Yan X; Yuan L; Yi H; Zhang L; Li B; Zhang Y; Sun J; Qiu MZ; Yang DJ Biochem Pharmacol; 2018 Aug; 154():127-135. PubMed ID: 29679556 [TBL] [Abstract][Full Text] [Related]
2. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523 [TBL] [Abstract][Full Text] [Related]
3. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells. Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337 [No Abstract] [Full Text] [Related]
4. The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma. Chen Z; Chen J; Liu H; Dong W; Huang X; Yang D; Hou J; Zhang X Front Pharmacol; 2018; 9():1298. PubMed ID: 30459627 [TBL] [Abstract][Full Text] [Related]
5. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027 [TBL] [Abstract][Full Text] [Related]
6. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Petersen SL; Peyton M; Minna JD; Wang X Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11936-41. PubMed ID: 20547836 [TBL] [Abstract][Full Text] [Related]
7. cIAP2 via NF-κB signalling affects cell proliferation and invasion in hepatocellular carcinoma. Jiang XJ; Chen ZW; Zhao JF; Liao CX; Cai QH; Lin J Life Sci; 2021 Feb; 266():118867. PubMed ID: 33310033 [TBL] [Abstract][Full Text] [Related]
8. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321 [TBL] [Abstract][Full Text] [Related]
9. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244 [TBL] [Abstract][Full Text] [Related]
10. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220 [TBL] [Abstract][Full Text] [Related]
11. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics. Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059 [TBL] [Abstract][Full Text] [Related]
13. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways. Di T; Luo QY; Song JT; Yan XL; Zhang L; Pan WT; Guo Y; Lu FT; Sun YT; Xia ZF; Yang LQ; Qiu MZ; Yang DJ; Sun J Int Immunopharmacol; 2024 Sep; 139():112615. PubMed ID: 39032475 [TBL] [Abstract][Full Text] [Related]
14. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs. Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105 [TBL] [Abstract][Full Text] [Related]
16. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540 [TBL] [Abstract][Full Text] [Related]
19. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell. Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880 [TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Darding M; Feltham R; Tenev T; Bianchi K; Benetatos C; Silke J; Meier P Cell Death Differ; 2011 Aug; 18(8):1376-86. PubMed ID: 21331077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]